Hamouda Boussen, MD
Clinician + Researcher
Title(s)
- Professor of Medicine (Medical Oncology), University Tunis El Manar, Faculty of Medicine Tunis
- President, Tunisian “PEC Consortium” (Protocole d’Etude en Cancérologie)
- Head, Department of Medical Oncology, Abderrahmen Mami Hospital, Ariana, Tunisia
Location(s)
- Abderrahmen Mami Hospital
- Medical Oncology Department
- Ariana, 2080
- Tunisia
- Phone: 00216 29 902626
Research and Clinical Interests
IBC-Focused Research
Dr. Boussen is a physician and researcher working on several areas of medical oncology. He conducted several clinical trials on breast cancer and inflammatory breast cancer and was one of lead researchers on this disease in Tunisia.
He contributed to the events of the Inflammatory Breast Cancer International Consortium (IBC-IC) with IBC International Conferences.
He organized the first International Workshop on IBC, in collaboration with IBC-IC and AFSOMA, which was held in Tunisia in 2019.
Clinical interests
- Breast Cancer
- Colorectal Cancer
- Head and Neck Cancer
- Lung Cancer
- Patient Advocacy
Affiliations and Memberships
- Board Member, Tunisia Society of Medical Oncology (STOM)
- University Tunis El Manar, Faculty of Medicine Tunis
- Laboratory of Biomedical Genomics and Oncogenetics, Institut Pasteur de Tunis, LR16IPT05, 1002, Tunis, Tunisia
- President, Association de Formation et de Sensibilisation à l’Oncologie Multidisciplinaire de l’Ariana (AFSOMA)
- European Society of Medical Oncology (ESMO)
- American Society of Medical Oncology (ASCO)
- AROME Cancer (Association de Radiotherapy and Oncology of Mediterranean arEa)
Recent Publications
Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer with lapatinib monotherapy
Journal of Clinical Oncology, 2008, 26(7), 1066-1072
Inflammatory breast cancer in Tunisia: epidemiological and clinical trends
Cancer, 2010, 116(S11), 2730-2735
Phase II study to evaluate the efficacy and safety of neoadjuvant lapatinib plus paclitaxel in patients with inflammatory breast cancer
Journal of Clinical Oncology, 2010, 28(20), 3248-3255
Inflammatory breast cancer in Tunisia: reassessment of incidence and clinicopathological features
Seminars in oncology, 2008, (Vol. 35, No. 1, pp. 17-24). WB Saunders
Breast cancer in Arab populations: molecular characteristics and disease management implications
The lancet oncology, 2013, 14(10), e417-e424
MARCKS protein overexpression in inflammatory breast cancer
Oncotarget, 2017, 8(4), 6246
More than 190 publications
Join IBC-IC
Become part of our international consortium of researchers, clinicians, advocates and centers worldwide dedicated to ending IBC.
Join >IBCIC.org makes every effort to keep researcher information as up-to-date as possible.
Contact this researcher to confirm any information regarding his or her profile.